Comparative Pharmacology
Head-to-head clinical analysis: CO LAV versus SODIUM SULFATE POTASSIUM SULFATE AND MAGNESIUM SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CO LAV versus SODIUM SULFATE POTASSIUM SULFATE AND MAGNESIUM SULFATE.
CO-LAV vs SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CO-LAV is a combination of codeine and acetylsalicylic acid (aspirin). Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and providing analgesic, antipyretic, and anti-inflammatory effects.
Osmotic laxative; induces bowel cleansing by retaining water in the intestinal lumen via osmotic effects, increasing intraluminal pressure and stimulating peristalsis.
Adults: 1 tablet (trimethoprim 80 mg/sulfamethoxazole 400 mg) orally twice daily for 5-7 days; for Pneumocystis jirovecii pneumonia, 2 tablets (160 mg/800 mg) orally every 6 hours for 21 days.
Oral: 3 packets (each containing 17.5g sodium sulfate, 3.13g potassium sulfate, and 1.6g magnesium sulfate) dissolved in water as a single dose, or as two doses: first packet in evening, second and third packets next morning. Route: oral. Frequency: single or split dose for colonoscopy preparation.
None Documented
None Documented
Unknown
Not applicable as intact drug; component electrolytes have variable half-lives: sulfate ~12-24 hours; potassium and magnesium are actively regulated with redistribution half-lives of minutes to hours.
CO-LAV is not a recognized drug. Please check the drug name.
Primarily renal: sulfate ions are excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
Category C
Category C
Laxative/Bowel Evacuant
Laxative